Drugs for Vein Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 82)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Epinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4 |
5816
|
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-Adrenalin
(−)-adrenaline
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(−)-adrenaline
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51028-73-0
51-43-4
51-43-4 (FREE BASE)
A0173
AC-13188
AC1L1L7B
Adnephrine
ADR ADRENALINE
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalina
Adrenalina [DCIT]
adrenaline
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalin-Medihaler
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
ADROP
AI3-19015
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthmahaler Mist
Asthmanefrin
Asthma-nefrin
Astmahalin
Astminhal
Balmadren
Bernarenin
BIDD:GT0119
Biorenine
bmse000316
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
Chelafrin
CHEMBL679
CID5816
Citanest Forte
Corisol
D00095
d-Adrenaline
DB00668
D-Epifrin
D-Epinephrine
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
epinephrine
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
EPIPEN E Z PEN
Epipen EZ Pen
EPIPEN JR
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
|
Eppy
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
HSCI1_000215
HSDB 4289
Hypernephrin
Hyporenin
Intranefrin
Iontocaine
IOP
Isoptoepinal
Kidoline
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
l-Epinephine
L-epinephrine
L-Epinephrine
l-Epinephrine (synthetic)
l-Epirenamine
L-Epirenamine
Levoadrenaline
levoepinephrine
Levoepinephrine
Levo-Methylaminoethanolcatechol
Levorenen
Levorenin
Levorenine
Levoreninum
l-Methylaminoethanolcatechol
L-Methylaminoethanolcatechol
Lopac-E-4642
LS-156
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
nchembio747-comp9
Nephridine
Nieraline
NSC 62786
NSC62786
Paranephrin
PDSP1_001120
PDSP2_001104
Primatene
Primatene Mist
R-(-)-Epinephrine
Racemic Epinephrine
Racepinephrine
R-Adrenaline
RCRA waste no. P042
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
Scurenaline
Septocaine
Simplene
Sindrenina
SMP1_000227
Soladren
Sphygmogenin
ST069368
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Susphrine
Sus-phrine
Sus-Phrine
SUS-PHRINE SULFITE-FREE
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
|
|
2 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676
|
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
|
Lanabiotic
L-Caine
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
3 |
|
Rivaroxaban |
Approved |
Phase 4 |
|
366789-02-8 |
|
Synonyms:
|
4 |
|
Sodium Tetradecyl Sulfate |
Approved, Investigational |
Phase 4 |
|
139-88-8, 1191-50-0 |
5248
14492
|
Synonyms:
1191-50-0
1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1)
1-Tetradecanol, hydrogen sulfate, sodium salt
22088-37-5
7-Ethyl-2-methyl-4-undecanol sulfate sodium salt
7-ethyl-2-methyl-4-undecanolsulfate, sodium salt
C14H28O5S
CHEMBL541505
CID14492
EINECS 214-737-2
LS-148911
Monotetradecylsulfate sodium salt
Monotetradecylsulphate sodium salt
Myristyl sulfate, sodium salt
Natri tetradecylsulfas
Natrii tetradecyclis sulfas
Natrii tetradecyclis sulfas [INN-Latin]
Natrii tetradecylis sulfa
Niaproof 4
NSC 139032
S.T.D
S.T.D.
Sodium 2-methyl-7-ethylundecanol-4-sulfate
Sodium 7-ethyl-2-methyl-4-undecanol sulfate
|
Sodium myristyl sulfate
Sodium myristyl sulphate
Sodium tetradecyl sulphate
Sodium tetradecylsulfate
Sotradecol Sodium
STDS
STS
Sulfuric acid, monotetradecyl ester, sodium salt
Sulfuric acid, myristyl ester, sodium salt
Tesapon K 14
Tetradecilsulfato sodico
Tetradecilsulfato sodico [INN-Spanish]
Tetradecyl hydrogen sulfate
Tetradecyl hydrogen sulphate
Tetradecyl sodium sulfate
Tetradecyl sodium sulphate
Tetradecyl sulfate
Tetradecyl sulfate de sodium
Tetradecyl sulfate de sodium [INN-French]
Tetradecyl sulfate, sodium salt
Tetradecyl sulfuric Acid
Tetradecyl sulphate
Texapon K 14
Trombavar
|
|
5 |
|
Racepinephrine |
Approved |
Phase 4 |
|
329-65-7 |
|
6 |
|
Polidocanol |
Approved |
Phase 4 |
|
9002-92-0 |
|
Synonyms:
Aethoxy-sklerol
Laureth 9
Laureth-9
Macrogol 9 lauryl ether
Nonaethylene glycol monododecyl ether
|
Nonaethylene glycol monolauryl ether
PEG-9 lauryl ether
Polydocanol
Polyethylene glycol 450 lauryl ether
Polyoxyl 9 lauryl ether
|
|
7 |
|
Anticoagulants |
|
Phase 4,Phase 3 |
|
|
|
8 |
|
Aminaftone |
|
Phase 4 |
|
|
|
9 |
|
Coagulants |
|
Phase 4,Phase 3 |
|
|
|
10 |
|
Hemostatics |
|
Phase 4,Phase 3 |
|
|
|
11 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
12 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
13 |
|
protease inhibitors |
|
Phase 4,Phase 3 |
|
|
|
Synonyms:
|
14 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
15 |
|
Central Nervous System Depressants |
|
Phase 4 |
|
|
|
16 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
17 |
|
Serine Proteinase Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
19 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
20 |
|
Mydriatics |
|
Phase 4 |
|
|
|
21 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
22 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
23 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
24 |
|
HIV Protease Inhibitors |
|
Phase 4,Phase 3 |
|
|
|
25 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
26 |
|
Anesthetics |
|
Phase 4 |
|
|
|
27 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
28 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
29 |
|
Peripheral Nervous System Agents |
|
Phase 4 |
|
|
|
30 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
31 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
32 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
33 |
|
Factor Xa Inhibitors |
|
Phase 4 |
|
|
|
34 |
|
Autonomic Agents |
|
Phase 4 |
|
|
|
35 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
36 |
|
Antithrombin III |
|
Phase 4 |
|
|
|
37 |
|
Antithrombins |
|
Phase 4 |
|
|
|
38 |
|
serine |
Nutraceutical |
Phase 4 |
|
|
|
39 |
|
Heparin |
Approved, Investigational |
Phase 3 |
|
9005-49-6 |
46507594
772
|
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
AR-1E4539
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID772
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
D006495
D017984
Dalteparin
Dalteparin sodium
DB00407
DB01225
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT966
EMT-966
EMT967
EMT-967
enoxaparin
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin Sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
|
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
LMWH
Logiparin
Lovenox
Lovenox HP
Low molecular weight heparin
Low Molecular Weight Heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
PK 10,169
PK10,169
PK-10,169
PK10169
PK-10169
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
40 |
|
Nadroparin |
Approved, Investigational |
Phase 3 |
|
9041-08-1 |
|
41 |
|
Dalteparin |
Approved |
Phase 3 |
|
9005-49-6 |
|
Synonyms:
|
42 |
|
calcium heparin |
|
Phase 3 |
|
|
|
43 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
44 |
|
Heparin, Low-Molecular-Weight |
|
Phase 3 |
|
|
|
45 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
46 |
|
Mitogens |
|
Phase 3 |
|
|
|
47 |
|
Angiogenesis Inducing Agents |
|
Phase 3 |
|
|
|
48 |
|
Angiogenesis Modulating Agents |
|
Phase 3 |
|
|
|
49 |
|
Anti-HIV Agents |
|
Phase 3 |
|
|
|
50 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 53)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Compression Aided Management of Edema in Patients With C3 Venous Disease |
Unknown status |
NCT00766974
|
Phase 4 |
|
2 |
Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein |
Completed |
NCT01368159
|
Phase 4 |
|
3 |
ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study. |
Completed |
NCT00509392
|
Phase 4 |
|
4 |
Iliac Vein Stenting in Advanced Chronic Venous Insufficiency |
Completed |
NCT02149212
|
Phase 4 |
Phlebotonic |
5 |
Rivaroxaban With Diosmine in Long-term Treatment of DVT |
Recruiting |
NCT03413618
|
Phase 4 |
Rivaroxaban;Diosmin |
6 |
Laser Ablation Versus Mechanochemical Ablation Trial |
Recruiting |
NCT02627846
|
Phase 4 |
Lidocaine with 1:200,000 epinephrine solution;Lidocaine with 1:200,000 epinephrine solution;Sodium Bicarbonate;Sodium Tetradecyl Sulphate |
7 |
Study of Antiinflammatory Effects of Detralex (Daflon) |
Enrolling by invitation |
NCT01654016
|
Phase 4 |
Detralex |
8 |
Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs |
Withdrawn |
NCT02988063
|
Phase 4 |
Polidocanol Endovenous Microfoam (PEM) |
9 |
Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT) |
Unknown status |
NCT00421538
|
Phase 3 |
nadroparine calcium;Placebo |
10 |
Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs |
Completed |
NCT01532882
|
Phase 3 |
Diosmin;Placebo |
11 |
The Influence of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Disease |
Completed |
NCT00196443
|
Phase 2, Phase 3 |
|
12 |
Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema |
Completed |
NCT01402921
|
Phase 3 |
|
13 |
Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing |
Not yet recruiting |
NCT02845466
|
Phase 3 |
|
14 |
Calcium Dobesilate for Chronic Venous Wounds |
Suspended |
NCT00979836
|
Phase 3 |
Calcium Dobesilate |
15 |
Great Saphenous Vein Electrocoagulation |
Unknown status |
NCT02139085
|
Phase 2 |
|
16 |
Non-Healing Ulcers Without Critical Limb Ischemia |
Unknown status |
NCT01666093
|
Phase 2 |
|
17 |
Treatment of Claudication With a Peristaltic Pulse Pneumatic Device |
Unknown status |
NCT01007604
|
Phase 2 |
|
18 |
Surface NeuroMuscular Electrical Stimulation in the Treatment of Chronic Venous Leg Ulcers |
Completed |
NCT01801891
|
Phase 2 |
|
19 |
Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation |
Completed |
NCT01509599
|
Phase 1, Phase 2 |
|
20 |
Physical Conditioning in Management of Chronic Venous Insufficiency |
Completed |
NCT00013273
|
Phase 2 |
|
21 |
EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR |
Withdrawn |
NCT02907320
|
Phase 2 |
CYCLO 3 ® FORT;MPFF;placebo CYCLO 3 ® FORT;placebo MPFF |
22 |
Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins |
Unknown status |
NCT01000909
|
|
|
23 |
Evaluating the Occurence of New and Progression of Existing Peripheral Venous Disease in Leg Veins |
Completed |
NCT00508079
|
|
|
24 |
Prevalence of Onychodystrophy in Patients With Chronic Venous Disease of the Lower Limbs |
Completed |
NCT02731222
|
|
|
25 |
Prevalence of MTHFR Polymorphisms in Venous Disease |
Completed |
NCT01993914
|
|
|
26 |
Estrogen Receptors and Chronic Venous Disease |
Completed |
NCT02558426
|
|
|
27 |
FOAM-study, Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins |
Completed |
NCT01103258
|
|
|
28 |
Epidemiology of Venous Disease |
Completed |
NCT00005392
|
|
|
29 |
Venous Insufficiency and Neuromuscular Stimulation |
Completed |
NCT02137499
|
|
|
30 |
Pen Torch Transillumination: Shedding Light on Difficult Venepuncture |
Completed |
NCT02570568
|
|
|
31 |
Copper Impact on Venous Insufficiency and Lipodermatosclerosis |
Completed |
NCT03283800
|
|
|
32 |
LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency |
Completed |
NCT03104985
|
|
|
33 |
Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome |
Completed |
NCT00395265
|
|
|
34 |
Non-Invasive Management of Chronic Venous Insufficiency |
Completed |
NCT00950378
|
|
|
35 |
Manual Lymphatic Drainage in Chronic Venous Insufficiency: a Randomized Controlled Trial |
Completed |
NCT01899482
|
|
|
36 |
Ongoing Registry of Treatment of Chronic Venous Diseases |
Recruiting |
NCT03035747
|
|
|
37 |
Elastic Compression in Chronic Venous Disease |
Recruiting |
NCT02641600
|
|
|
38 |
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE". |
Recruiting |
NCT02841085
|
|
|
39 |
Effect of Standing, Lying and Stockings on Blood Bio-markers (v.1) |
Recruiting |
NCT02662127
|
|
|
40 |
Haemorrhages and Thromboembolic Venous Disease of the Postpartum |
Recruiting |
NCT02443610
|
|
|
41 |
Treatment of Insufficient Superficial and Perforating Veins of the Lower Limb Using HIFU |
Recruiting |
NCT03304834
|
|
|
42 |
Retinal Thrombosis and Atherosclerosis |
Recruiting |
NCT02257333
|
|
|
43 |
Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department |
Recruiting |
NCT02706080
|
|
|
44 |
Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure |
Recruiting |
NCT03206372
|
|
|
45 |
Bern Venous Stent Registry |
Recruiting |
NCT02433054
|
|
|
46 |
Sinai Vein Stent Registry |
Recruiting |
NCT02600936
|
|
|
47 |
FireFly Vein Finder: Venepuncture Made Easy |
Active, not recruiting |
NCT03202238
|
|
|
48 |
Ecchymosis and Coldness in Patients With Varicose Vein |
Not yet recruiting |
NCT03384355
|
|
|
49 |
Vein Fitness System vs Compressive Therapy for Venous Ulcers: a Bayesian Adaptive Trial |
Not yet recruiting |
NCT03127904
|
|
|
50 |
Effect of VarIthena on Wound Healing in VLU |
Not yet recruiting |
NCT03257254
|
|
Varithena |
|